



## **Aligos Therapeutics to Present 28-Day Safety, Efficacy and Pharmacokinetic Data for CAM Drug Candidate ALG-000184 and Nonclinical Data for Two Additional Chronic Hepatitis B Programs at the European Association for the Study of the Liver's International Liver Congress™ 2022**

### **Data presented on three chronic hepatitis B programs in Aligos' chronic hepatitis B portfolio**

SOUTH SAN FRANCISCO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company will present three posters highlighting data from three of the company's programs in chronic hepatitis B (CHB) at the European Association for the Study of the Liver's International Liver Congress 2022 (EASL ILC 2022), taking place June 22 -26, 2022 at the ExCeL London Exhibition Centre in London, UK.

The posters are expected to be made available to conference attendees at the beginning of the sessions during which the posters will be presented, Saturday, June 25, 2022, 9 a.m. BST. The posters will be available subsequently on the "Scientific Presentation and Publications" page in the "Presentations" section of Aligos' website at [www.aligos.com](http://www.aligos.com).

Presentation details for each abstract accepted to date are listed below.

**Poster number:** 782

**Poster title:** Safety, pharmacokinetics, and antiviral activity of the class II capsid assembly modulator ALG-000184 in subjects with chronic hepatitis B

**Presenter:** Professor Man-Fung Yuen, MBBS, M.D., Ph.D., DSc, University of Hong Kong, Hong Kong

**Poster session title:** Viral hepatitis B/D: therapy

**Date and time of poster session:** Saturday, June 25, 2022, 9 a.m. BST

**Poster number:** 1410

**Poster title:** The HBV siRNA, ALG-125755, demonstrates a favourable nonclinical profile and significant and durable hepatitis B surface antigen reductions in the AAV-HBV mouse efficacy model

**Presenter:** Megan Fitzgerald, Ph.D.

**Poster session title:** Viral hepatitis B/D: therapy

**Date and time of poster session:** Saturday, June 25, 2022, 9 a.m. BST

**Poster number:** 1627

**Poster title:** Discovery of oral PDL1 small molecule inhibitors specifically designed for the treatment of chronic hepatitis B

**Presenter:** Francois Gonzalvez, Ph.D.

**Poster session title:** Viral hepatitis B/D: therapy

**Date and time of poster session:** Saturday, June 25, 2022, 9 a.m. BST

"We are pleased to present progress related to three of Aligos' programs in our chronic hepatitis B portfolio," said Lawrence Blatt, Ph.D., MBA, Chairman and Chief Executive Officer of Aligos. "By continuing to advance a diverse CHB portfolio, we aim to be able to evaluate multiple approaches to providing better outcomes for patients with CHB."

The conference will announce a second set of accepted abstracts before the beginning of the congress, which may include other abstracts submitted by Aligos.

### **About Aligos**

Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos' strategy is to harness the deep expertise and decades of drug development experience its team has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.

Please visit [www.aligos.com](http://www.aligos.com) for more information.

### **Forward-Looking Statement**

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered "forward-looking statements." Forward-looking statements are typically, but not always, identified by the use of words such as "may," "will," "would," "believe," "intend," "plan," "anticipate," "estimate," "expect," and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including Aligos' clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug candidates, Aligos' ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of Aligos' capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape and the effects on our business of the worldwide COVID-19 pandemic and the developing conflict between Russia and Ukraine. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos' Annual Report on Form 10-K filed with the Securities and

Exchange Commission on March 10, 2022, as well as other documents Aligos files from time to time with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

**Media Contact**

Amy Jobe, Ph.D.  
LifeSci Communications  
+1 315 879 8192  
ajobe@lifescicomms.com

**Investor Contact**

Corey Davis, Ph.D.  
LifeSci Advisors  
+1 212 915 2577  
cdavis@lifesciadvisors.com